Logo image
Continuous Infusion 5-Fluorouracil with Bolus Adriamycin and Mitomycin and Low-Dose Cisplatin (FAMP) in the Treatment of Metastatic Gastric Carcinoma: An Evaluation of Efficacy and Toxicity
Journal article   Peer reviewed

Continuous Infusion 5-Fluorouracil with Bolus Adriamycin and Mitomycin and Low-Dose Cisplatin (FAMP) in the Treatment of Metastatic Gastric Carcinoma: An Evaluation of Efficacy and Toxicity

James W. Raschko, Elizabeth A. Johnson, Winston Ueno, Paul V. Woolley, Joseph Treat and Ebony A Johnson
Cancer investigation, v 9(1)
1991
PMID: 2012996

Abstract

Abstract A pilot study was performed to evaluate the feasability of administering prolonged continuous infusion 5-fluorouracil with multiple bolus chemotherapeutic agents. Twelve patients with advanced measurable gastric carcinoma were treated with a combination chemotherapy program of continuous infusion 5-fluorouracil, bolus Adriamycin, mitomycin C, and low-dose cisplatin (FAMP). Responses were observed in 5 patients (2 complete and 3 partial). Observed toxicities included leukopenia, thrombocytopenia, mucositis, and hand-foot syndrome. Although the FAMP regimen has activity in advanced gastric carcinoma, the number of patients evaluated was small and significant improvement over currently available regimens could not be demonstrated. Evaluation of toxicities indicates that bolus administration of multiple agents (specifically, Adriamycin, mitomycin C, and cisplatin) can be used in conjunction with continuously infused 5-fluorouracil without excessive toxicity.

Metrics

11 Record Views
3 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image